Antibody therapy as a future treatment option for Ebola virus infection

Future Virology

Volumn 2, Issue 6, 2007, Pages 607-614

  Matsuno, Keita ^a   Takada, Ayato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antibopdy therapy; Ebola virus; Monodonal antibody; Passive immunization

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; STRUCTURAL PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ANTIBODY SPECIFICITY; BABOON; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; EBOLA VIRUS; EXPERIMENTAL MODEL; GUINEA PIG; HUMAN; MEDICAL RESEARCH; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; VIRION; VIRUS HEMORRHAGIC FEVER; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION;

ANIMALIA; CAVIA; EBOLA VIRUS; MUS; PRIMATES;

EID: 36349008769     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.6.607     Document Type: Review

References (52)

1. Sanchez A, Geisbert TW, Feldmann H: Filoviridae: Marburg and Ebola viruses. In: Fields Virology 5th Edition. Knipe DM, Howley PM (Eds.), Lippincott-Williams & Wilkins, PA, USA 1409-1448 (2007).
2. Geisbert TW, Hensley LE: Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev. Mol. Med. 6(20), 1-24 (2004).
3. Leroy EM, Kumulungui B, Pourrut X et al.: Fruit bats as reservoirs of Ebola virus. Nature 438(7068), 575-576 (2005).
4. Alvarez CP, Lasala F, Carrillo J et al.: C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76(13), 6841-6844 (2002).
5. Chan SY, Empig CJ, Velte FJ et al.: Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106(1), 117-126 (2001).
6. Shimojima M, Takada A, Ebihara H et al.: Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80(20), 10109-10116 (2006).
7. Takada A, Fujioka K, Tsuiji M et al.: Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78(6), 2943-2947 (2004).
8. Takada A, Watanabe S, Ito H et al.: Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278(1), 20-26 (2000).
9. Takada A, Kawaoka Y: Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13(6), 387-398 (2003).
10. Mohamadzadeh M, Chen L, Schmaljohn AL: How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol. 7(7), 556-567 (2007).
11. Ito H, Watanabe S, Takada A, Kawaoka Y: Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75(3), 1576-1580 (2001).
12. Dolnik O, Volchkova V, Garten W et al.: Ectodomain shedding of the glycoprotein GP of Ebola virus. Embo J. 23(10), 2175-2184 (2004).
13. Reed DS, Mohamadzadeh M: Status and challenges of filovirus vaccines. Vaccine 25(11), 1923-1934 (2007).
14. Bukreyev A, Rollin PE, Tate MK et al.: Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81(12), 6379-6388 (2007).
15. Jones SM, Feldmann H, Stroher U et al.: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11(7), 786-790 (2005).
16. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812), 605-609 (2000).
17. Olinger GG, Bailey MA, Dye JM et al.: Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol. 79(22), 14189-14196 (2005).
18. Sullivan NJ, Geisbert T, Geisbert J et al.: Mechanism of immune protection against Ebola virus infection in non-human primates. Presented at: XIII International Conference on Negative Strand Viruses. Salamanca, Spain, 21 June 2006.
19. Sullivan NJ, Geisbert TW, Geisbert JB et al.: Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3(6), e177 (2006).
20. Maruyama T, Rodriguez LL, Jahrling PB et al.: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73(7), 6024-6030 (1999).
21. Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB: Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology 293(1), 15-19 (2002).
22. Takada A, Ebihara H, Feldmann F, Geisbert TW, Kawaoka Y: Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. (2007) (In press)
23. Emond RT, Evans B, Bowen ET, Lloyd G: A case of Ebola virus infection. Br. Med. J. 2(6086), 541-544 (1977).
24. Mupapa K, Massamba M, Kibadi K et al.: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179(Suppl. 1), S18-S23 (1999).
25. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG: Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J. Infect. Dis. 179(Suppl. 1), S24-S27 (1999).
26. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE: Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75(10), 4649-4654 (2001).
27. Jahrling PB, Geisbert TW, Geisbert JB et al.: Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179(Suppl. 1), S224-234 (1999).
28. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV: Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J. Infect. Dis. 179 (Suppl. 1), S218-S223 (1999).
29. Borisevich IV, Mikhailov VV, Krasnianskii VP et al.: Development and study of the properties of immunoglobulin against Ebola fever. Vopr. Virusol. 40(6), 270-273 (1995).
30. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP: The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr. Virusol. 39(2), 82-84 (1994).
31. Jahrling PB, Geisbert J, Swearengen JR et al.: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. (Suppl. 11), S135-S140 (1996).
32. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y: Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77(13), 7539-7544 (2003).
33. Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y: Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75(5), 2324-2330 (2001).
34. Takada A, Ebihara H, Jones S, Feidmann H, Kawaoka Y: Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25(6), 993-999 (2007).
35. Takada A, Feldmann H, Stroeher U et al.: Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77(2), 1069-1074 (2003)
36. Lefranc MP, Giudicelli V, Kaas Q et al.: IMGT, the international ImMunoGeneTics information system. Nucleic. Acids. Res. 33(Database issue), D593-D597 (2005).
37. Druar C, Saini SS, Cossitt MA et al.: Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus soluble glycoprotein. Immunogenetics 57(10), 730-738 (2005).
38. Maruyama T, Parren PW, Sanchez A et al.: Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179(Suppl. 1), S235-S239 (1999).
39. Shahhosseini S, Das D, Qiu X et al.: Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J. Virol. Methods 143(1), 29-37 (2007).
40. Wilson JA, Hevey M, Bakken R et al.: Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458), 1664-1666 (2000).
41. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR: Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76(12), 6408-6412 (2002).
42. Oswald WB, Geisbert TW, Davis KJ et al.: Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3(1), E9 (2007).
43. Hevey M, Negley D, Schmaljohn A: Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 314(1), 350-357 (2003).
44. Cardenas WB, Loo YM, Gale M, Jr. et al.: Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80(11), 5168-5178 (2006).
45. Feng Z, Cerveny M, Yan Z, He B: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 81(1), 182-192 (2007).
46. Reid SP, Leung LW, Hartman AL et al.: Ebola virus VP24 binds laryopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80(11), 5156-5167 (2006).
47. Geisbert TW, Young HA, Jahrling PB et al.: Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188(11), 1618-1629 (2003).
48. Geisbert TW, Hensley LE, Jahrling PB et al.: Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400), 1953-1958 (2003).
49. Mahanty S, Hutchinson K, Agarwal S et al.: Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6), 2797-2801 (2003).
50. Bosio CM, Aman MJ, Grogan C et al.: Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188(11), 1630-1638 (2003).
51. Geisbert TW, Hensley LE, Gibb TR et al.: Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80(2), 171-186 (2000).
52. Geisbert TW, Hensley LE, Larsen T et al.: Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163(6), 2347-2370 (2003).